Vasopressin's effects on acquisition and extinction of conditioned avoidance response to smoking.
Lysine-8-vasopressin (LVP) 5 I.U. or NaCl was administered intranasally daily for 5 days in a double blind study to 14 women and 7 men volunteers, 30 minutes prior to aversive conditioning sessions designed to assist them to stop smoking. Subjects were asked to record the number of urges to smoke, the strength of their strongest urge to smoke and the number of cigarettes smoked on a daily basis. Adequate data was obtained from 17 subjects for the Lead-in (pretreatment) week and for the Treatment week. Of these, 10 continued to supply sufficient responses through the sixth week of follow-up. During the week of aversive conditioning those subjects receiving LVP smoked significantly fewer cigarettes than the saline treatment group (p less than 0.01). During the Follow-up period the LVP group had significantly more urges to smoke than the saline group (p less than 0.01). The LVP group also smoked significantly more cigarettes than the saline group 4 weeks (p less than 0.05) and 6 weeks (0.01) after the Treatment week. LVP was associated with a facilitation of the acquisition of the avoidance response to smoking followed by an apparent acceleration of the extinction of the avoidance response compared to saline.
D000293:Adolescent; D000328:Adult; D001362:Avoidance Learning / Q000187:drug effects*; D003213:Conditioning, Psychological / Q000187:drug effects*; D005108:Extinction, Psychological / Q000187:drug effects*; D005260:Female; D006801:Humans; D008236:Lypressin / Q000494:pharmacology*; D008297:Male; D000074606:Smoking Prevention
D008236:Lypressin